Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritonea...( Montreal Canada June 28 2001 ...)

Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritoneal dialysis

Montreal, Canada, June 28, 2001 - Data presented from the largest randomized controlled clinical trial ever completed in dialysis patients suggest that peritoneal dialysis (PD), a flexible home-based dialysis treatment for people with chronic kidney failure, might have far broader applicability than current practice patterns suggest. This study, led by researchers in Mexico and conducted under the auspices of the Mexican healthcare authorities , and supported by Baxter Healthcare Corporation and its Mexico affiliate, was presented this week at an invited scientific session at the IX Congress of the International Society for Peritoneal Dialysis (ISPD) in Montreal.

According to Peter G. Blake, M.D., associate professor of medicine at the University of Western Ontario, Canada, and member of the National Kidney Foundation Dialysis Outcomes Quality Initiative (DOQI) Peritoneal Dialysis Adequacy Workgroup, "This is a pivotal study for the nephrology community worldwide because it is a high quality, multi-center, prospective, randomized, controlled trial with a large number of patients, which gives us highly credible results. The study provides us with statistically sound evidence for simplifying our PD treatment practices-without sacrificing patient outcomes. The findings, which challenge existing treatment recommendations for peritoneal dialysis, should make it significantly easier for physicians to prescribe peritoneal dialysis and may also make it possible for many more patients to benefit from the therapy."

Declining kidney function results in higher levels of toxins and waste products in the blood. When the kidneys no longer adequately eliminate toxins from the bloodstream, peritoneal dialysis helps to clear these unwanted substances through the peritoneal membrane, commonly measured in terms of small solute clearances like urea and creatinine. This membrane, located in the abdominal region, serves as the therapy's natural waste filter and
'"/>

Contact: Stephanie Lazor
stephanie.lazor@mslpr.com
212-213-7265
Manning Selvage & Lee
28-Jun-2001

Page: 1 2 3 4 5
Related medicine news :

1. Landmark survey reveals asthma in children remains significantly out of control in the United States
2. Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR
3. Landmark study shows coenzyme Q10 slows progressive decline in Parkinsons disease
4. Landmark XENDOS study shows Xenical prevents or delays the development of type 2 diabetes
5. Landmark study demonstrates potential for nerve regeneration treatment of stroke
6. Landmark study results published in NEJM highlight breakthrough treatment for heart failure
7. Landmark study uncovers reasons behind recurring back injury
8. Landmark clinical trial at 22 medical centers finds implanted heart pumps lengthen and improve lives of terminally ill heart failure patients
9. Landmark school-based social influences smoking-prevention program found not to work
10. U.S., British scientific societies honor penicillin as International Chemical Landmark
11. CODE-2*: Landmark study on the costs of type 2 diabetes in Europe

Post Your Comments: